# OSE Immunotherapeutics

> Biotech, drug development, immuno-oncology, immuno-inflammation

Business model and tags: B2B, Pharma & life sciences, Multi-site, Has in-house R&D, Handles regulated data

## About OSE Immunotherapeutics

Develops first-in-class assets in immuno-oncology and immuno-inflammation, including therapeutic cancer vaccines, monoclonal antibodies for solid tumors, ulcerative colitis, and chronic inflammation, and transplant.

## Key facts

- **Industry**: Biotechnology Research
- **Company size**: 51–250 employees
- **Headquarters**: Nantes, Brittany, France
- **Founded**: 2012
- **Revenue**: €2.7M (FY2025, publicly reported)
- **SIREN**: [479457715](https://annuaire-entreprises.data.gouv.fr/entreprise/479457715)
- **Website**: [ose-immuno.com](ose-immuno.com)
- **LinkedIn**: [linkedin.com/company/ose-immunotherapeutics](https://www.linkedin.com/company/ose-immunotherapeutics)

## OSE Immunotherapeutics at a glance

OSE Immunotherapeutics is a B2B company in the Biotechnology Research industry, headquartered in Nantes, Brittany, France.

OSE Immunotherapeutics was founded in 2012.

OSE Immunotherapeutics has 51–250 employees.

OSE Immunotherapeutics's revenue is €2.7M (FY2025, publicly reported).

OSE Immunotherapeutics's SIREN number is 479457715.

## Frequently asked questions about OSE Immunotherapeutics

### What is OSE Immunotherapeutics's revenue?

OSE Immunotherapeutics's revenue is €2.7M (FY2025, publicly reported).

### How many employees does OSE Immunotherapeutics have?

OSE Immunotherapeutics has 51–250 employees.

### Where is OSE Immunotherapeutics headquartered?

OSE Immunotherapeutics is headquartered in Nantes, Brittany, France.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/ose-immunotherapeutics
